Evidence map›Paper›PMID 38617636›Full record

ArticleACS omega2024

Development and Optimization of Proniosomal Formulation of Irbesartan Using a Box-Behnken Design to Enhance Oral Bioavailability: Physicochemical Characterization and

Md Ali Mujtaba, Mohammed Kaleem, Ragini Chaware, Ashwini Ingole, Yahya I Asiri, Mohd Zaheen Hassan, Vidya Sabale, Prafulla Sabale, Md Khalid Anwer, Danish Mahmood and 1 more

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Escitalopram oxalate-loaded chitosan nanoparticleFrontiers in pharmacology · 2025
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Md Ali MujtabaDepartment of Pharmaceutics, Faculty of Pharmacy, Northern Border University, Arar 91911, Saudi Arabia.ORCID https://orcid.org/0000-0002-6372-890X
Mohammed KaleemDepartment of Pharmacology, Dadasaheb Balpande College of Pharmacy, Rashtrasant Tukadoji Maharaj Nagpur University Nagpur, Nagpur 440034, Maharashtra, India.ORCID https://orcid.org/0000-0003-4681-2031
Ragini ChawareDepartment of Pharmaceutics, Dadasaheb Balpande College of Pharmacy, Rashtrasant Tukadoji Maharaj Nagpur University Nagpur, Nagpur 440034, Maharashtra, India.
Ashwini IngoleDepartment of Pharmaceutics, Dadasaheb Balpande College of Pharmacy, Rashtrasant Tukadoji Maharaj Nagpur University Nagpur, Nagpur 440034, Maharashtra, India.
Yahya I AsiriDepartment of Pharmacology, College of Pharmacy, King Khalid University, Asir 61421, Saudi Arabia.
Mohd Zaheen HassanDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Asir 61421, Saudi Arabia.
Vidya SabaleDepartment of Pharmaceutics, Dadasaheb Balpande College of Pharmacy, Rashtrasant Tukadoji Maharaj Nagpur University Nagpur, Nagpur 440034, Maharashtra, India.ORCID https://orcid.org/0000-0001-9685-1341
Prafulla SabaleDepartment of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur 440033, Maharashtra, India.
Md Khalid AnwerDepartment of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, P.O. Box 173, Al-Kharj 11942, Saudi Arabia.
Danish MahmoodDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia.
Mohammed F AldawsariDepartment of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, P.O. Box 173, Al-Kharj 11942, Saudi Arabia.
Rashtrasant Tukadoji Maharaj Nagpur University · INKing Khalid University · SAPrince Sattam Bin Abdulaziz University · SANorthern Border University · SAQassim University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This research work aimed to develop and evaluate proniosomes for the oral delivery of the lipophilic drug Irbesartan (IRB) to improve its solubility and bioavailability. Proniosomes of Irbesartan were formulated using a lipid, surfactant, and carrier by a slurry method. Based on the prepared preliminary trial batches and their evaluation, the formulation was optimized by employing a Box-Behnken design (BBD) in which concentrations of span 60 (

Identifiers

PMID38617636
PMCPMC11007800
OpenAlexW4393160877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.